AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22350244 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic CBD exploration
Number of subjects: 256
Study 22350244 — intervention group
Group type: COMPARATOR
Intervention: Open CBD exploration
Number of subjects: 256
Study 20067715 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused extracorporeal shock wave therapy (0.20 mJ/mm(2))
Number of subjects: 39
Study 20067715 — intervention group
Group type: COMPARATOR
Intervention: Radial extracorporeal shock wave therapy (0.17 mJ/mm(2))
Number of subjects: 39
Study 17530270 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine (2%) with adrenaline (1:80,000)
Number of subjects: 30
Study 17530270 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine (2%)
Number of subjects: 30
Study 16123708 — intervention group
Group type: EXPERIMENTAL
Intervention: GuttaFlow (GF)
Number of subjects: 90
Study 16123708 — intervention group
Group type: COMPARATOR
Intervention: conventional cold laterally condensed gutta‐percha (LC)
Number of subjects: 90
Study 16123708 — intervention group
Group type: COMPARATOR
Intervention: warm vertically condensed gutta‐percha (VC)
Number of subjects: 90
Study 12373694 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral somatic nerve block (PVB)
Number of subjects: 46
Study 12373694 — intervention group
Group type: COMPARATOR
Intervention: Peripheral block (PB)
Number of subjects: 46
Study 12373694 — intervention group
Group type: EXPERIMENTAL
Intervention: PVB
Number of subjects: 46
Study 12373694 — intervention group
Group type: COMPARATOR
Intervention: PB
Number of subjects: 46
Study 9988787 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-knife conization
Number of subjects: 180
Study 9988787 — intervention group
Group type: COMPARATOR
Intervention: Loop electrosurgical excision procedure
Number of subjects: 180
Study 7494110 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone plus a beta‐lactamase stable antibiotic for 10 days, with responders receiving an additional six weeks of chemoprophylaxis.
Number of subjects: 122
Study 7494110 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control group).
Number of subjects: 122
Study 7494110 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone plus a beta‐lactamase stable antibiotic.
Number of subjects: 122
Study 2176898 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut oil
Number of subjects: 0
Study 2176898 — intervention group
Group type: COMPARATOR
Intervention: Medium chain triglyceride
Number of subjects: 0
Study 2176898 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 with food
Number of subjects: 0
Study 2176898 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut oil and medium chain triglyceride
Number of subjects: 0
Study 7439263 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of ketoprofen (capsule)
Number of subjects: 0
Study 7439263 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of ketoprofen
Number of subjects: 0
Study 7439263 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal administration of ketoprofen (suppository)
Number of subjects: 0
Study 7439263 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of ketoprofen
Number of subjects: 0
Study 7439263 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated oral administration of ketoprofen (50 mg q.i.d.)
Number of subjects: 0
Study 7439263 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of ketoprofen
Number of subjects: 0
Study 7439263 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 31815790 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate endpoints including glomerular filtration rate slope, albuminuria, donor-specific alloantibodies, and histological score at graft protocol biopsies.
Number of subjects: 0
Study 31815790 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical multiple primary endpoints using surrogate endpoints.
Number of subjects: 0
Study 31815790 — intervention group
Group type: EXPERIMENTAL
Intervention: New clinical endpoints focusing on treatment safety and patient quality of life.
Number of subjects: 0
Study 31182123 — intervention group
Group type: EXPERIMENTAL
Intervention: eConsult access for 1 year
Number of subjects: 113
Study 31182123 — intervention group
Group type: COMPARATOR
Intervention: No access to eConsult (Control)
Number of subjects: 113
Study 28178008 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid Nitrogen (LN2)
Number of subjects: 24
Study 28178008 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,1,1,2-tetrafluoroethane (TFE)
Number of subjects: 24
Study 28178008 — intervention group
Group type: COMPARATOR
Intervention: No additional cooling treatment (Control)
Number of subjects: 24
Study 25808994 — intervention group
Group type: EXPERIMENTAL
Intervention: CNI-free (everolimus with half-dose EC-MPS 720 mg/day and cyclosporine withdrawal)
Number of subjects: 194
Study 25808994 — intervention group
Group type: COMPARATOR
Intervention: CNI (continue cyclosporine with standard EC-MPS)
Number of subjects: 194
Study 23668026 — intervention group
Group type: EXPERIMENTAL
Intervention: Decoction of invigorating Qi and clearing lung combined with standardized myrtol (300 mg, 3 times a day)
Number of subjects: 98
Study 23668026 — intervention group
Group type: COMPARATOR
Intervention: Standardized myrtol (300 mg, 3 times a day)
Number of subjects: 98
Study 21030470 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained seating force during bonding (300 g for 3 seconds, maintained for 40 seconds during curing)
Number of subjects: 40
Study 21030470 — intervention group
Group type: COMPARATOR
Intervention: Initial seating force (300 g for 3 seconds, no sustained force)
Number of subjects: 40
Study 21030470 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 19472007 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaker exercise
Number of subjects: 19
Study 19472007 — intervention group
Group type: COMPARATOR
Intervention: Traditional swallowing therapy
Number of subjects: 19
Study 19472007 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 19
Study 17592789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (80 mg/day)
Number of subjects: 0
Study 17592789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (160 mg/day)
Number of subjects: 0
Study 17592789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (mean dose)
Number of subjects: 0
Study 17592789 — intervention group
Group type: COMPARATOR
Intervention: Not treating (control)
Number of subjects: 0
Study 15213497 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricortical screw fixation (2 screws, 3.5-mm each)
Number of subjects: 64
Study 15213497 — intervention group
Group type: COMPARATOR
Intervention: Quadricortical screw fixation (1 screw, 4.5-mm)
Number of subjects: 64
Study 11588528 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg, once daily)
Number of subjects: 9
Study 11588528 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg, once daily)
Number of subjects: 9
Study 11588528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9849987 — intervention group
Group type: EXPERIMENTAL
Intervention: Three dose primary schedule (2, 4, 6 months)
Number of subjects: 236
Study 9849987 — intervention group
Group type: COMPARATOR
Intervention: Two dose primary schedule (3, 5 months)
Number of subjects: 236
Study 9849987 — intervention group
Group type: EXPERIMENTAL
Intervention: Both schedules after booster vaccinations
Number of subjects: 236
Study 7851356 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine and methyl-atropine administered 2 minutes after rocuronium (Group B)
Number of subjects: 60
Study 7851356 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine and methyl-atropine administered at 25% twitch recovery (Group C)
Number of subjects: 60
Study 7851356 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine and methyl-atropine administered at spontaneous recovery (Group A)
Number of subjects: 60
Study 2577692 — intervention group
Group type: EXPERIMENTAL
Intervention: dilevalol
Number of subjects: 8
Study 2577692 — intervention group
Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 8
Study 68454 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (i.m.) injection of bleomycin
Number of subjects: 110
Study 68454 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) injection of bleomycin
Number of subjects: 110
Study 68454 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 110
Study 30659994 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week conditional cash transfer intervention followed by a 4-week cognitive-behavioural aftercare group (CCT + AC)
Number of subjects: 600
Study 26482136 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Educational System (TES) with Contingency Management (CM) component, earning up to $600 in prizes over 12 weeks for providing drug negative urines and completing web-based cognitive behavior therapy modules.
Number of subjects: 255
Study 26482136 — intervention group
Group type: COMPARATOR
Intervention: Usual care counseling (without TES).
Number of subjects: 255
Study 25174443 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioline® (albumin-heparin coating)
Number of subjects: 30
Study 25174443 — intervention group
Group type: COMPARATOR
Intervention: Phisio® (phosphorylcholine polymer coating)
Number of subjects: 30
Study 25174443 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 23740194 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antioxidant therapy (allopurinol, α-lipoic acid, and nicotinamide)
Number of subjects: 44
Study 23740194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 21610398 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop training
Number of subjects: 14
Study 21610398 — intervention group
Group type: EXPERIMENTAL
Intervention: On-the-job (OTJ) training
Number of subjects: 14
Study 21610398 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster training
Number of subjects: 14
Study 19843804 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia
Number of subjects: 0
Study 19843804 — intervention group
Group type: COMPARATOR
Intervention: Neuraxial analgesia
Number of subjects: 0
Study 16621227 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dissection of the rectus sheath inferiorly during Pfannenstiel incision
Number of subjects: 120
Study 16621227 — intervention group
Group type: COMPARATOR
Intervention: Dissection of the rectus sheath inferiorly during Pfannenstiel incision
Number of subjects: 120
Study 12736891 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant wearing of multipolar, static magnetic (450G) shoe insoles
Number of subjects: 375
Study 12736891 — intervention group
Group type: COMPARATOR
Intervention: Placebo group wearing similar, unmagnetized device
Number of subjects: 375
Study 11061537 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 U/kg Escherichia coli endotoxin
Number of subjects: 6
Study 11061537 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 6
Study 9223025 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA 4.0 mumol/min i.v.
Number of subjects: 8
Study 9223025 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐arg (30 mumol/kg‐min i.v.)
Number of subjects: 8
Study 9223025 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 8
Study 8335541 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (10 g/kg body wt)
Number of subjects: 23
Study 8335541 — intervention group
Group type: COMPARATOR
Intervention: Moderate-carbohydrate diet (5 g/kg body wt)
Number of subjects: 23
Study 2952606 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and intracoronary thrombolysis with transluminal coronary angioplasty
Number of subjects: 127
Study 2952606 — intervention group
Group type: COMPARATOR
Intervention: Intravenous and intracoronary thrombolysis without transluminal coronary angioplasty
Number of subjects: 127
Study 29878035 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 µg vitamin D3/d (400 IU)
Number of subjects: 144
Study 29878035 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 µg vitamin D3/d (800 IU)
Number of subjects: 144
Study 29878035 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 µg vitamin D3/d)
Number of subjects: 144
Study 27394029 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up antibody testing after RBC transfusions
Number of subjects: 100
Study 27394029 — intervention group
Group type: COMPARATOR
Intervention: No follow-up antibody screen or testing too soon (<30 days) after transfusion
Number of subjects: 100
Study 27394029 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up testing 30 to 112 days posttransfusion
Number of subjects: 100
Study 27394029 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up testing more than 112 days posttransfusion
Number of subjects: 100
Study 27394029 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing at both 30 to 112 days and more than 112 days
Number of subjects: 100
Study 24057100 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular resonance (MR)‐induced tonsil thermal ablation
Number of subjects: 62
Study 24057100 — intervention group
Group type: COMPARATOR
Intervention: Standard bipolar dissection tonsillectomy
Number of subjects: 62
Study 22340993 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 10mg/kg as a bolus preoperatively followed by 1mg/kg as a maintenance dose intra operatively
Number of subjects: 50
Study 22340993 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 50
Study 20206835 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/day for 8 weeks
Number of subjects: 27
Study 20206835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 18319058 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg ilaprazole
Number of subjects: 21
Study 16450827 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel nutritional immune formula (NNIF)
Number of subjects: 200
Study 16450827 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 200
Study 12857764 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training program (6 months of physical therapy, strength training, and walking followed by 3 months of endurance exercise at 78% of peak heart rate)
Number of subjects: 46
Study 12857764 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training program
Number of subjects: 46
Study 12857764 — intervention group
Group type: COMPARATOR
Intervention: Control sedentary group
Number of subjects: 46
Study 10675246 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear liquid diet
Number of subjects: 44
Study 10675246 — intervention group
Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 44
Study 8693765 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR pacing
Number of subjects: 23
Study 8693765 — intervention group
Group type: COMPARATOR
Intervention: DDD pacing
Number of subjects: 23
Study 2003858 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (6 mg/day)
Number of subjects: 24
Study 2003858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6856363 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate at lower dosages
Number of subjects: 0
Study 6856363 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate at higher dosages
Number of subjects: 0
Study 6856363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31062264 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 100
Study 31062264 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Number of subjects: 100
Study 30342551 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanxinjing capsule (GXJ)
Number of subjects: 120
Study 30342551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 27914885 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assisted percutaneous liver biopsy
Number of subjects: 102
Study 27914885 — intervention group
Group type: COMPARATOR
Intervention: Percussion guided technique
Number of subjects: 102
Study 24608207 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Number of subjects: 31
Study 24608207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 22507611 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater length-for-age
Number of subjects: 158
Study 22507611 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater weight-for-age
Number of subjects: 158
Study 22507611 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of daily complementary feeding
Number of subjects: 158
Study 19850529 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard urotherapy and pelvic floor exercises
Number of subjects: 75
Study 19850529 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 75
Study 19850529 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received pharmacotherapy (anticholinergics or desmopressin) as needed
Number of subjects: 75
Study 18628671 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally negative words perceived by the left visual cortex
Number of subjects: 0
Study 18628671 — intervention group
Group type: COMPARATOR
Intervention: Emotionally negative words perceived by the right visual cortex
Number of subjects: 0
Study 16203877 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (70 mg orally per week for twenty‐five weeks)
Number of subjects: 40
Study 16203877 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication or placebo)
Number of subjects: 40
Study 16203877 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 40
Study 16203877 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 12548208 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometritis/UGTI (defined as >or=5 neutrophils or >or=2 plasma cells, Neisseria gonorrhoeae or Chlamydia trachomatis upper genital tract infection)
Number of subjects: 614
Study 12548208 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometritis/UGTI
Number of subjects: 614
Study 10860128 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 775
Study 10860128 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 775
Study 8657762 — intervention group
Group type: EXPERIMENTAL
Intervention: gel containing lysated keratinocyte cultures
Number of subjects: 20
Study 8657762 — intervention group
Group type: COMPARATOR
Intervention: placebo-gel
Number of subjects: 20
Study 8657762 — intervention group
Group type: COMPARATOR
Intervention: fresh keratinocyte alloculture
Number of subjects: 20
Study 2072138 — intervention group
Group type: EXPERIMENTAL
Intervention: IT MTX without cranial irradiation (MTX group)
Number of subjects: 77
Study 2072138 — intervention group
Group type: EXPERIMENTAL
Intervention: IT MTX and 18 Gy cranial irradiation (18-Gy group)
Number of subjects: 77
Study 2072138 — intervention group
Group type: EXPERIMENTAL
Intervention: IT MTX and 24 Gy cranial irradiation (24-Gy group)
Number of subjects: 77
Study 2072138 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 77
Study 2072138 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 77
Study 6125203 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg
Number of subjects: 0
Study 6125203 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 100 mg
Number of subjects: 0
Study 6125203 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 0
Study 6125203 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 200 mg
Number of subjects: 0
Study 6125203 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (various doses)
Number of subjects: 0
Study 6125203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31335174 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) intervention group
Number of subjects: 60
Study 31335174 — intervention group
Group type: COMPARATOR
Intervention: Traditional Occupational Therapy (TOT) intervention group
Number of subjects: 60
Study 31104833 — intervention group
Group type: EXPERIMENTAL
Intervention: Burosumab (0.8 mg/kg every 2 weeks)
Number of subjects: 61
Study 31104833 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (oral phosphate and active vitamin D)
Number of subjects: 61
Study 31104833 — intervention group
Group type: EXPERIMENTAL
Intervention: Burosumab
Number of subjects: 61
Study 31104833 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 61
Study 31104833 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 61
Study 28135050 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom Care at Home (SCH)
Number of subjects: 358
Study 28135050 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (UC)
Number of subjects: 358
Study 27192359 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone text messaging education (10 text messages during hospitalization to first follow-up)
Number of subjects: 61
Study 27192359 — intervention group
Group type: COMPARATOR
Intervention: Conventional textual and verbal information
Number of subjects: 61
Study 23757034 — intervention group
Group type: EXPERIMENTAL
Intervention: Complicated appendicitis (Group 2)
Number of subjects: 49
Study 23757034 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncomplicated appendicitis (Group 1)
Number of subjects: 49
Study 23757034 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific abdominal pain (Group 3)
Number of subjects: 49
Study 23757034 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 levels
Number of subjects: 49
Study 22537763 — intervention group
Group type: EXPERIMENTAL
Intervention: Total estrogen metabolites
Number of subjects: 188
Study 22537763 — intervention group
Group type: EXPERIMENTAL
Intervention: 2/16α‐OH ratio
Number of subjects: 188
Study 22537763 — intervention group
Group type: EXPERIMENTAL
Intervention: 2/16α‐OHE(1) ratio
Number of subjects: 188
Study 22537763 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐OH pathway
Number of subjects: 188